Arrowhead Pharmaceuticals (NASDAQ:ARWR) COO Sells $3,123,503.23 in Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) COO Patrick O’brien sold 49,493 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $3,123,503.23. Following the transaction, the chief operating officer owned 474,908 shares in the company, valued at $29,971,443.88. This represents a 9.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR opened at $65.69 on Thursday. The firm has a market capitalization of $8.93 billion, a PE ratio of -821.02 and a beta of 1.21. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $76.76. The business’s 50 day moving average is $56.34 and its 200-day moving average is $35.95.

Key Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Multiple firms raised price targets (Goldman Sachs to $85, Morgan Stanley to $81, Chardan to $80), signaling renewed analyst optimism about Arrowhead’s prospects and giving the share price directional upside. Article Title
• Positive Sentiment: Arrowhead released interim Phase 1/2a obesity data showing meaningful fat reductions and a combination result that nearly doubled four‑month weight loss with tirzepatide — news that triggered investor interest and bullish media coverage. Article Title
• Positive Sentiment: Unusually heavy call‑option activity and earlier intraday spikes indicate speculative/bullish positioning around the obesity data. Article Title
• Neutral Sentiment: Some analysts and commentators flagged small sample sizes and incomplete datasets in the obesity update, meaning clinical significance and reproducibility remain uncertain until larger cohorts and full data are published. Article Title
• Negative Sentiment: Arrowhead filed to sell $500M of convertible senior notes due 2032 and $200M of common stock — a material capital raise that raises dilution and financing‑cost concerns for equity holders. Article Title
• Negative Sentiment: Large insider sales by senior executives (multiple recent Form 4 filings showing significant share disposals) are adding to market concern about near‑term selling pressure. Article Title

Analyst Upgrades and Downgrades

ARWR has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Morgan Stanley increased their target price on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a report on Wednesday. Piper Sandler boosted their price target on Arrowhead Pharmaceuticals from $70.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. The Goldman Sachs Group upped their price target on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday. Finally, Bank of America lifted their price objective on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $71.89.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. iSAM Funds UK Ltd acquired a new position in Arrowhead Pharmaceuticals in the third quarter worth $29,000. Virtus Advisers LLC bought a new position in shares of Arrowhead Pharmaceuticals in the second quarter valued at about $34,000. Salomon & Ludwin LLC acquired a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth about $34,000. Nisa Investment Advisors LLC grew its holdings in Arrowhead Pharmaceuticals by 75.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 1,308 shares during the last quarter. Finally, Federated Hermes Inc. bought a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth about $52,000. 62.61% of the stock is owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.